Print This Page

Complete References

Bradley J. Monk, MD

[1](Monk - figure 5) Jemal A et al. CA Cancer J Clin. 2012

[2](Monk - figure 5) Saslow D et al. CA Cancer J Clin. 2007;57:7-28.

[3](Monk - figure 5) ACS. Facts & Figures. 2009.

[4](Monk - figure 6) Chesson H et al. Persp Sex Repro Health. 2004;36:11-19.

[5](Monk - figure 6) Clifford G et al. Cancer Epidemiol Biomarkers Prev. 2005;14:1157-64.

[6](Monk - figure 6) Smith J et al. Int J Cancer. 2007;121:621-32.

[7](Monk - figure 6) Data on File. GlaxoSmithKline.

[8](Monk - figure 7) Centers for Disease Control and Prevention. Genital HPV Infection
Fact Sheet. http://www.cdc.gov/STD/HPV/STDFact-HPV.htm.

[9](Monk - figure 8) Ostor A. Int J of Gynecol Path. 1993;12:186-92.

[10](Monk - figure 8) Moscicki A et al. Vaccine. 2006;24S3:42-51.

[11](Monk - figure 8) Einstein M. Cancer Immunol Immunother. 2008;57:443-51.

[12](Monk - figure 8) Winer R et al. J Inf Dis. 2005;191:731-38.

[13](Monk - figure 8) Holowaty P et al. J Natl Cancer Inst. 1999;91:252-58. 6. Solomon D et al. JAMA. 2002;287:2114-19.

[14](Monk - figure 9) Schiffman M, Kjaer SK. J Int Cancer Natl Monogr. 2003;31:14-19;

[15](Monk - figure 9) Ostör AG. Int J Gynecol Pathol. 1993;12:186-192;

[16](Monk - figure 9) Schiffman M et al. Lancet. 2007;370:890-907;

[17](Monk - figure 9) Bory JP et al. Int J Cancer. 2002;102:519-525;

[18](Monk - figure 9) Ho GY et al. N Engl J Med. 1998;338:423-428;

[19](Monk - figure 9) Nobbenhuis MA et al. Lancet. 1999;354:20-25.

[20](Monk - figure 10) Cox. Obstet Gynecol. 1995;9:1.

[21](Monk - figure 10) Munoz et al. N Engl J Med. 2003;348:518.

[22](Monk - figure 10) ACOG Practice Bulletin, Number 99. Obstet Gynecol. 2008;112:1419-1444.

[23](Monk - figure 11) Jansen KU, Shaw AR. Annu Rev Med. 2004;55:319–331.

[24](Monk - figure 11) Insinga RP, Dasbach EF, Myers ER. Clin Infect Dis. 2003;36:1397–1403.

[25](Monk - figure 11) Koutsky L. Am J Med. 1997;102:3–8.

[26](Monk - figure 12) Clifford GM, Smith JS, Aguado T, Franceschi S. Br J Cancer. 2003:89;101–105.

[27](Monk - figure 13) Melkert PW et al. Int J Cancer. 1993;53:919-323;

[28](Monk - figure 13) Ries LAG et al. eds. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute. Bethesda, MD.
Available at: http://seer.cancer.gov/csr/1975_2005;

[29](Monk - figure 13) Sherman ME et al. J Natl Cancer Inst. 2003;95:46-52; 4. Rozendaal L et al. Int J Cancer. 1996;68:766-769.

[30](Monk - figure 14) ACOG Committee on Practice Bulletins–Gynecology. Obstet Gynecol. 2009;114:1409-1420.

[31](Monk - figure 15) Leyden et al. J Natl Cancer Inst. 2009;114:1409-1420.

[32](Monk - figure 16) Petry KU et al. Br J Cancer. 2003;88:1570-1577;

[33](Monk - figure 16) Cuzick J et al. Br J Cancer. 1999;81:554-558;

[34](Monk - figure 16) Salmerón J et al. Cancer Causes Control. 2003;14:505-512;

[35](Monk - figure 16) Schiffman M et al. JAMA. 2000;283:87-93;

[36](Monk - figure 16) Wright TC Jr et al. JAMA. 2000;283:81-86;

[37](Monk - figure 16) Belinson J et al. Gynecol Oncol. 2001;83:439-444;

[38](Monk - figure 16) Mayrand MH et al. N Engl J Med. 2007;357:1579-1588;

[39](Monk - figure 16) Clavel C et al. Br J Cancer. 2001;89:1616-1623;

[40](Monk - figure 16) Sherman ME et al. J Natl Cancer Inst. 2003;95:46-52;

[41](Monk - figure 16) Lörincz A, Richart R. Arch Pathol Lab Med. 2003;127:959-968.

Xian Wen Jin, MD, PhD

[42](Jin - figure 5) Nanda K. et al. Ann Intern Med, 2000; 132:810-819

[43](Jin - figure 5) ACOG Practice Bulletin 61. 2005;61:3

[44](Jin - figure 5) Evaluation of Cervical Cytology. Summary, Evidence Report/Technology Assessment: Number 5, January 1999.

[45](Jin - figure 5) Agency for Health Care Policy and Research, Rockville, MD.
Available at: http://www.ahrq.gov/clinic/epcsums/cervsumm.htm

[46](Jin - figure 8, figure 26, figure 30, figure 41) Cervical cytology screening. ACOG Practice Bulletin No.109. American College of Obstetrics and Gynecology. Obstet Gynecol 2009; 114:1409-1420

[47](Jin - figure 9) Biscotti, C.V. et al. (2005) Am. J. Clin. Pathol

[48](Jin - figure 9) Clavel, C. et al. (2001) Br. J. Cancer

[49](Jin - figure 9) Cytyc Package Insert: ThinPrep® Imaging System, Table 2.

[50](Jin - figure 9, figure 12, figure 25) Mayrand, M.H. et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl J Med 2007; 357(16):1579-1588.

[51](Jin - figure 9, figure 12, figure 14, figure 15, figure 16, figure 17, figure 25) Ronco, G. et al. Human Papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst 2006; 98(11):765-774

[52](Jin - figure 10) Ries, L.A.G. et al. eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute
Available at: http://seer.cancer.gov/csr/1975_2005.

[55](Jin - figure 12) Bulkmans N W J et al. Lancet 2007;370:1764-1772

[56](Jin - figure 12) Naucler P et al. N Engl J Med 2007;357:1589-97

[57](Jin - figure 12) Kitchener H. C et al. Lancet Oncol 2009;10(7):672-682

[58](Jin - figure 18, figure 20) N Engl. J Med. 2007; 357(16):1579-88.

[59](Jin - figure 19) Table 4. N Engl. J Med. 2007; 357(16):1579-88.

[60](Jin - figure 21) Dillner, J. et al. BMJ 2008;337:a1754

[61](Jin - figure 22, figure 23, figure 24, figure 25) Sankaranarayanan, R. et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360(14):1385-1394.

[62](Jin - figure 25) CDC Study (Datta et al., Annals of Internal Medicine, 2008)

[63](Jin - figure 25) Castle, PE, et al. Obstet Gynecol 2009;113:595–600

[64](Jin - figure 25) European Cohort Study (Dillner, J. et al., BMJ, 2008)

[65](Jin - figure 26) Saslow, D. et al. CA Cancer J . Clin. 2002;52:342-362.

[66](Jin - figure 26) SPSTF. Screening for Cervical Cancer. Accessed January 2003.
Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.pdf.

[67](Jin - figure 26) Wright, T et al. Obstet. Gynecol. 2004;103:304–9.

[68](Jin - figure 26) Wright, T. et al. J. Low. Genit.Tract Dis. 2007;11(4):201-22.

[69](Jin - figure 26) American Society for Colposcopy and Cervical Pathology. HPV Genotyping Clinical Update. 2009.
Available at: http://www.asccp.org/Portals/9/docs/pdfs/Consensus%20Guidelines/clinical_update_20090408.pdf.

[70](Jin - figure 26, figure 28, figure 30, figure 38) Saslow, D. et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and detection of cervical cancer. Am J. Clin Pathol 2012;137:516-542.

[71](Jin - figure 26, figure 29, figure 30) Moyer, VA. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation state. Annal of Internal Medicine 2012.
Available at: http://www.annals.org/content/early/2012/03/14/0003-4819-156-12-201206190-00424.full.

[72](Jin - figure 38) American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology. Screening Guidelines: Supplementary Report. 2012.

[73](Jin - figure 39) ACOG Practice Bulletin, Number 99. Obstet Gynecol

[74](Jin - figure 39) Mayrand, M-H., Duarte-Franco, E., NEJM (2007)

[75](Jin - figure 40) Castle et al. Ob. Gynecol. 2009;113:18-25
Image at: www.aafp.org/afp/20060101/105.html

[76](Jin - figure 42) Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. Am J Obstet Gynecol. 2007 Oct;197(4):346-55.

[77](Jin - figure 43) Chelmow, D. et al. Obstet. Gynecol. 2012;119:695-699.

[78](Jin - figure 44) IOM. Clinical Preventive Services for Women: Closing the Gaps. Washington DC: National Academies Press; 2011.
Available at: http://www.nap.edu/catalog.php?record_id=13181.

[79](Jin - figure 44) HRSA. Women’s preventive services: Required health plan coverage guidelines.
Available at: http://www.hrsa.gov/womensguidelines/.

Nancy R. Berman, MSN

[88](Berman - figure 6) Wallboomers JM, et. Al. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.

[89](Berman - figure 6) Koutsky L Am J Med 1997; Dunne EF. J Infect Dis. 2006; Dunne EF. JAMA. 2007.

[90](Berman - figure 6, figure 7) CDC , Human Papillomavirus: HPV Information for Clinicians, November, 2006

[91](Berman - figure 6) Winer RL, Hughes JP, “Condom use and the risk of genital human papillomavirus infection in young women”, N Eng J Med. 2006. Jun 22;354(25):2645-54.

[92](Berman - figure 6) Ho GYF, Bierman R, Beardsley L, Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8.

[93](Berman - figure 7) Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24S1:S1/4-S1/15.

[94](Berman - figure 8, figure 9, figure 10, figure 11, figure 12, figure 20, figure 23) Saslow D, Solomon D, et al “American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer, Journal of Lower Genital Tract Disease, 2012;6;(3):175-204.

[95](Berman - figure 12) Ho GYF, Bierman R, Beardsley L, Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-8

[96](Berman - figure 13) Cervical Cytology Screening. ACOG Practice Bulletin No. 109. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009; 114:1409–20.

[97](Berman - figure 14) Committee Opinion #483, "Primary and Preventive Care: Periodic Assessments," April 2011 issue of Obstetrics & Gynecology.

[98](Berman - figure 14) Committee Opinion #534 "Well –Woman Visit" American College of Obstetricians and Gynecologists, August 2012.

[99](Berman - figure 17) McCree DH, Sharpe PA, et. al., Preference for sources of information about abnormal Pap tests and HPV in women tested for HPV, Prev Med. 2006 Sep;43(3): 165-70.